REGULATORY

PAFSC OKs Seikagaku’s Osteoarthritis Med for Use Excluding Ankle Joints, Bayer’s Larotrectinib Too

February 1, 2021

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

A key health ministry advisory panel cleared Seikagaku’s osteoarthritis medicine diclofenac conjugated sodium hyaluronate at its second attempt on January 29, with the product’s label expected to exclude its use in ankle joints. With this nod, the drug could land…

To read the full story

Japan Approves Incyte’s Pemazyre, Bayer’s Vitrakvi, Novartis’ Kesimpta, and More
March 24, 2021
MHLW Approves Add’l Use for Thaled, Bavencio and More
February 25, 2021

REGULATORY

Chuikyo OKs Listing of J&J’s Rybrofaz, Peak Sales Seen at 43.8 Billion Yen
March 12, 2026
GSK’s Exdensur, Lilly’s Inluriyo Missing from March Listing Roster
March 12, 2026
Truqap Price Cut Set at 10.7% from June under CEA Scheme
March 12, 2026
Avelox Gains Coverage for MDR-TB via Public Knowledge Filing
March 12, 2026
Council Floats 9.6% Growth Target for Japan’s On-Patent Drug Market
March 11, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Elevidys Opens New Era for DMD Treatments Targeting the Underlying Cause

By Shinya Sato

Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…